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Abstract
Primary hyperparathyroidism is an endocrine disorder with variable
clinical expression, frequently presenting as asymptomatic hypercal-
cemia in Western countries but still predominantly as a symptomatic
disease in developing countries. The objective of this retrospective
study was to describe the diagnostic presentation profile, parathyroi-
dectomy indication and post-surgical bone mineral density follow-up
of patients with primary hyperparathyroidism seen at a university
hospital. We found 115 patients (92 women, median age 56 years)
with primary hyperparathyroidism diagnosed during the last 20 years.
We defined symptomatic patients based on the presence of any
classical symptom affecting bone, kidney or the neuromuscular sys-
tem. Surgical criteria followed the guidelines of the National Institutes
of Health regarding asymptomatic primary hyperparathyroidism.
Symptomatic patients and patients meeting surgical criteria for para-
thyroidectomy were 66 and 93% of the sample, respectively. Median
calcium and parathyroid hormone values were 11.9 mg/dL and 189
pg/mL, respectively. After surgical treatment, 97% of patients were
cured, with increases in bone mineral density of 19.4% in the lumbar
spine and 15.7% in the femoral neck 3 years after surgery. Greater
bone mass increases were detected in pre-menopausal women, men,
and in symptomatic and younger patients, both in the lumbar spine
and femoral neck. Our results support the previous findings of a
predominantly symptomatic disease with a presentation profile that
could be mainly related to a delayed diagnosis. Nevertheless, genetic
and racial backgrounds, and nutritional factors such as calcium and
vitamin D deficiency may play a role in the clinical presentation of
primary hyperparathyroidism of Brazilian patients.
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Introduction
Primary hyperparathyroidism (PHP) is
an endocrine disorder characterized by hy-
percalcemia and elevated or inappropriately
normal levels of parathyroid hormone. In its
early descriptions, the classical disease was
associated with involvement of the kidneys
(renal calculi and nephrocalcinosis), skel-
eton (osteitis fibrosa cystica, with pain, patho-
logical fractures and deformity), and neuro-
muscular system (proximal neuromuscular
weakness) (1). In the 1970’s, after the intro-
duction of automated and routine measure-
ment of serum calcium levels in developed
countries, several studies reported a sharp
increase in the diagnosis of PHP (2). The
increased incidence of PHP in these coun-
tries was associated with a significant change
in the presentation of the clinical spectrum
of the disease. Most cases were asympto-
matic at diagnosis, as opposed to the classi-
cal disease description (3).
In this context, studies currently conducted
in Western countries show that less than 20%
of the patients present symptomatic PHP, i.e.,
PHP with the early described classical fea-
tures (4). Parathyroidectomy is indicated for
these cases. Management guidelines deal spe-
cifically with the asymptomatic form of the
disease. Following these guidelines, approxi-
mately 50% of the PHP patients will meet one
or more criteria for parathyroidectomy, even
though most of these patients are asymptomat-
ic (5). In contrast to these findings, studies in
developing countries like India, China, Brazil,
and others still show a high incidence of symp-
tomatic cases (6-9). Late diagnosis, related to
limited access to routine measurement of cal-
cium levels and/or poor recognition of PHP,
as well as the possible high prevalence of
vitamin D deficiency in these countries, may
lead to a more symptomatic clinical profile
(10). However, as we have demonstrated in a
recent study, the proportion of symptomatic
cases is gradually but still slowly decreasing in
our public service (11).
We reviewed our PHP data regarding the
clinical and laboratory findings before and
after surgical treatment during the last 20
years. The main purposes of the present
study were to analyze the diagnostic presen-
tation and surgical indication profile of PHP
and the recovery of bone mineral density
(BMD) after parathyroidectomy in our pa-
tients, in São Paulo.
Patients and Methods
The study was retrospective and evaluated
PHP patients followed at the Bone Metabo-
lism Unit of the Federal University of São
Paulo (UNIFESP). Reports of all patients with
PHP diagnosed between 1985 and 2004 were
reviewed. Since this is a reference service,
most patients are referred to it by other special-
ties. The diagnosis of PHP was mainly based
on calcium measurements ordered during the
follow-up of menopausal patients or during
the investigation of bone diseases and urolithi-
asis. Calcium measurement was not used as a
routine screening method.
The diagnostic criterion for PHP was
based on hypercalcemia (total calcium lev-
els ≥10.5 mg/dL and/or ionized calcium lev-
els above the upper normal reference range)
associated with high or inappropriately nor-
mal intact parathyroid hormone levels (iPTH,
normal range 10-65 pg/mL). Patients with
renal insufficiency, defined as creatinine >1.5
mg/dL, were excluded when kidney disease
was not related to PHP.
A total of 131 PHP patients were diag-
nosed during the last 20 years. Of this group,
16 were excluded, 5 due to the fact that PHP
was related with multiple endocrine neopla-
sia type 1, 3 because of familial isolated
PHP, and 8 because of renal insufficiency
that was not related to PHP.
The remaining 115 patients with spo-
radic PHP were classified as symptomatic or
asymptomatic according to the presence of
classical hyperparathyroidism findings, de-
fined as clinical or radiological bone dis-
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ease, nephrolithiasis, proximal neuromus-
cular weakness, and hospital admission re-
lated to hypercalcemic complications.
Asymptomatic patients were further classi-
fied into surgical and non-surgical accord-
ing to the criteria established by the National
Institutes of Health Workshop on Asympto-
matic PHP (12,13). Surgical criteria included
age below 50 years, serum calcium concen-
trations 1 mg/dL above the upper normal
limit, nephrolithiasis, 24-h urinary calcium
excretion above 400 mg, and densitometric
osteoporosis of the lumbar spine or hip.
Patients satisfying at least one criterion were
scheduled for parathyroidectomy, while the
asymptomatic patients who did not meet
surgical criteria were followed clinically.
Patients classified as symptomatic fulfilled
at least one such criterion and were all sub-
mitted to surgery. Data about perioperative
and late postoperative complications as well
as pathological findings were also reviewed.
Until 1993 (N = 21 patients), parathyroid
hormone levels were measured by an amino-
terminal specific radioimmunoassay. As of
1994, iPTH levels were measured by an
immunofluorimetric assay. The median para-
thyroid hormone values calculated in this
study refer only to these iPTH data obtained
by immunofluorimetric assay. Total calcium
levels were measured by colorimetric assays
and ionized calcium with an ion-specific
electrode. Bone densitometry of the lumbar
spine (L1-L4) and femoral neck was ob-
tained by dual-energy X-ray absorptiometry
(DEXA) using Hologic QDR 4500 (Wal-
tham, MA, USA) and Lunar DPX (Madison,
WI, USA) devices. Measurements were al-
ways performed with the same device for
each patient. The coefficient of variation
based on repeated measurements with a spine
phantom was lower than 0.5% for both de-
vices and the service coefficient of variation
was 3.5% for both lumbar spine and femoral
neck. Absolute Hologic BMD data were con-
verted to Lunar data for calculation and com-
parison of mean and median parameters and
for the determination of longitudinal changes.
Conversion equations were as follows, as
defined elsewhere (14):
Lunar DPXlumbar spine = (1,074 x Hologic
QDRlumbar spine) + 0.054
Lunar DPXfemoral neck = (1,013 x Hologic
QDRfemoral neck) + 0.142
Patients were classified as osteoporotic
when the BMD T-score was lower than -2.5
SD in relation to young adults from the
DEXA manufacturer’s database, according
to the definition established by the World
Health Organization.
Statistical analysis
Data are reported as median or means ±
SD. Statistical comparisons were performed
using the Student t-test and the Mann-Whit-
ney test for quantitative variables and the χ2
test for qualitative variables. BMD data were
assessed by analysis of variance (ANOVA)
to evaluate changes relative to baseline. A P
Table 1. Baseline clinical and laboratory data of patients with primary hyperparathy-
roidism.
Reference range
Women 80% (92/115)     -
Age (years) (age range) 56.0 (11 to 86)     -
Symptomatic patients 66% (74/112)     -
Patients with surgical criteria 93% (107/115)     -
Osteoporosis 71% (72/101)     -
Nephrolithiasis 39% (43/111)     -
24-h urinary calcium ≥400 mg 28% (27/96)     -
Calcium >1 mg/dL above the UNL 59% (64/109)     -
Age ≤50 years 31% (36/115)     -
Serum calcium (mg/dL) 11.9 (109/115) 8.5-10.5
Ionized calcium (mmol/L) 1.52 (101/115) 1.20-1.40
iPTH (pg/mL) 189.0 (95/115) 10-65
Serum phosphorus (mg/dL) 2.1 (102/115) 2.5-4.5
Alkaline phosphatase (IU/L) 254 (100/115) 80-250
Serum creatinine (mg/dL) 0.9 (106/115) 0.6-1.5
24-h urinary calcium (mg) 308.0 (91/115) 60-220
Data are reported as median or percentage. UNL = upper normal limit; iPTH = intact
parathyroid hormone.
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value equal to or lower than 0.05 was taken
to indicate a significant difference.
Results
The baseline clinical and laboratory data
of PHP patients are reported in Table 1.
Classical PHP signs and symptoms were
detected in 66% of the sample. When com-
pared to the asymptomatic patients, these
symptomatic patients presented higher se-
rum calcium, iPTH and urinary calcium lev-
els and lower phosphorus levels (Table 2).
However, even among the remaining asymp-
tomatic patients, 79% also fulfilled at least
one surgical criterion. Thus, as a whole, only
7% of these patients were not surgical candi-
dates and 93% met at least one surgical
criterion at presentation. The main surgical
criteria were lumbar spine and/or femoral
neck densitometric osteoporosis (71%) and
total calcium 1 mg/dL above the upper nor-
mal limit (59%). Nephrolithiasis (39%), age
less than 50 years (31%) and 24-h urinary
calcium higher than 400 mg (28%) were less
prevalent (Table 1).
Clinical and densitometric follow-up of the
operated patients
Follow-up data were available for most
of the 115 patients, 93% (N = 107) were
scheduled for parathyroidectomy, but only
84% (N = 90) of them were operated. Pa-
tients were not operated either because their
clinical conditions did not permit surgery or
because they did not accept the procedure.
These patients, as well as the asymptomatic
patients who did not meet the surgical crite-
ria, are currently being followed clinically.
Table 3. Bone mineral density (BMD) evolution of the operated patients with primary hyperparathyroidism at
baseline and at 12 and 36 months after surgery.
Baseline 12 months ∆1 P* 36 months ∆2 P+
(N = 65) (N = 30) (N = 55)
Lumbar spine BMD 0.823 ± 0.188 0.902 ± 0.136 9.6% <0.01 0.983 ± 0.169 19.4% <0.01
(g/cm2)
Femoral neck BMD 0.718 ± 0.171 0.795 ± 0.130 10.7% <0.01 0.831 ± 0.162 15.7% <0.01
(g/cm2)
Data are reported as means ± SD. ∆1 and ∆2 are the respective relative increases (in percent) in BMD at 12
and 36 months after surgery compared to baseline BMD.
*Compared to baseline BMD (ANOVA); +compared to baseline and to a 12-month period BMD (ANOVA).
Table 2. Comparison of laboratory and bone mineral density (BMD) parameters of symptomatic and asympto-
matic patients with primary hyperparathyroidism.
Symptomatic patients Asymptomatic patients Reference range
Serum calcium (mg/dL) 12.7 11.2* 8.5-10.5
Parathyroid hormone (pg/mL) 256.5 138.5* 10-65
Alkaline phosphatase (IU/L) 264.5 245.0 80-250
Serum phosphorus (mg/dL) 2.05 2.40* 2.5-4.5
24-h urinary calcium (mg) 332.0 242.0* 60-220
Lumbar spine BMD (g/cm2) 0.823 ± 0.200 0.820 ± 0.146 -
Femoral neck BMD (g/cm2) 0.707 ± 0.174 0.739 ± 0.131 -
Data are reported as median or means ± SD.
*P < 0.05 compared to symptomatic patients (Mann-Whitney test).
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Of the operated patients, 30% needed intra-
venous calcium after surgery, 5% had transi-
tory dysphonia and 2% had a cervical he-
matoma. After parathyroidectomy, all pa-
tients were discharged with a prescription of
oral calcium and vitamin D supplements.
The main pathological finding was parathy-
roid adenoma (77%). Parathyroid hyperpla-
sia and carcinoma were found in 10 and 9%,
respectively, while 4% had uncertain histo-
pathological findings. Seventy-eight patients
were followed up for a mean period of 47
months after surgery. Five patients (6%)
were successfully submitted to a second sur-
gery because of a first non-curative surgery
for a parathyroid adenoma. Almost all pa-
tients (97%) submitted to parathyroidectomy
were cured. Only 6% became permanently
hypocalcemic. Five patients with histologi-
cal parathyroid carcinoma with capsular and
vascular invasion were normocalcemic dur-
ing a mean follow-up period of 24 months
after surgery, whereas three patients re-
mained hypercalcemic and died during fol-
low-up.
BMD increased significantly after sur-
gery both in the lumbar spine (9.6% in 12
months and 19.4% in 36 months) and femo-
ral neck (10.7% within 12 months and 15.7%
within 36 months), as shown in Table 3. We
analyzed these patients according to clinical
parameters at presentation in order to find
differences in bone mass evolution during
the follow-up after surgery for a median
period of 36 months (Table 4). All patient
groups had significant increases in bone mass
both in the lumbar spine and femoral neck.
Asymptomatic patients who were not oper-
ated upon because they were not surgical
candidates continued to have stable BMD
during this period (-1% in the lumbar spine
and 4% in the femoral neck). When we
Table 4. Bone mineral density (BMD) evolution of primary hyperparathyroidism patients according to clinical parameters at baseline and after a
median period of 36 months after curative parathyroidectomy.
Lumbar spine BMD Femoral neck BMD
 (g/cm2) (g/cm2)
Baseline 36 months ∆ P* P+ Baseline 36 months ∆ P* P+
Premenopausal 0.875±0.277 1.032±0.250 18% <0.01 0.707±0.289 0.968±0.177 37% <0.01
women (N = 12)
Postmenopausal 0.824±0.145 0.929±0.118 13% <0.01 0.03 0.716±0.133 0.784±0.144 10% <0.01 <0.01
women (N = 42)
Men (N = 11) 0.758±0.218 1.042±0.207 38% <0.01 0.736±0.144 0.878±0.128 19% <0.01
Age ≤50 years 0.833±0.248 1.076±0.188 29% <0.01 0.729±0.237 0.931±0.167 28% <0.01
(N = 22) 0.05 0.05
Age >50 years 0.817±0.152 0.937±0.139 15% <0.01 0.711±0.130 0.782±0.137 10% <0.01
(N = 43)
Patients with 0.758±0.161 0.954±0.172 26% <0.01 0.661±0.151 0.887±0.147 34% <0.01
osteoporosis (N = 49) <0.01 0.05
Patients without 1.020±0.114 1.095±0.096 7% 0.05 0.792±0.103 0.975±0.134 23% <0.01
osteoporosis (N = 16)
Symptomatic patients 0.823±0.200 1.017±0.174 23% <0.01 0.707±0.174 0.841±0.174 19% <0.01
operated (N = 35)
Asymptomatic patients 0.820±0.146 0.917±0.140 12% <0.01 <0.01 0.739±0.131 0.810±0.139 10% <0.01 <0.01
operated (N = 20)
Asymptomatic patients 1.065±0.161 1.061±0.099 -1% 0.37 0.861±0.189 0.895±0.056 4% 0.85
not operated (N = 6)
Data are reported as means ± SD. ∆ = percent increase in BMD between baseline and 36 months after surgery.
*Compared to baseline BMD for each parameter (ANOVA); +comparison between groups regarding BMD increase 36 months after surgery
(ANOVA).
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compared data between groups, we found
greater bone mass increases in premeno-
pausal women, in men, and in symptomatic
and younger patients, both in the lumbar
spine and femoral neck (Table 4).
Discussion
We observed that the pattern of clinical
PHP presentation in our institution is mainly
symptomatic, but we point out that only 115
patients were diagnosed between 1985 and
2004 at a reference public service. We think
this low figure could be related to a delayed
PHP diagnosis and to a still low recognition
of the disease. In a city like São Paulo, with
more than 10 million people, 115 patients
diagnosed in 20 years at a reference service
is far from the expected figure if we consider
a prevalence of about 3/1000 in the general
population (15). Most patients had a severe
clinical and laboratory diagnostic presenta-
tion, probably as a result of several hyper-
calcemia complications owing to a late diag-
nosis. Perhaps only the more severe cases
are referred to this service. The high preva-
lence of parathyroid carcinoma seen in our
study could also be related to this selection
bias, since it is much higher than the values
reported in the Western literature (16), al-
though similar prevalences have been found
in other studies from developing countries
(6,17). Nevertheless, we emphasize that this
presentation profile is gradually changing,
as stated by Ohe et al. (11), who studied most
of these patients and observed that the diag-
nostic incidence of PHP as well as the pro-
portion of asymptomatic patients slowly in-
creased in the last few years.
Due to the high prevalence of sympto-
matic cases (66%), it was not a surprise that
the majority of these patients were sent to
surgery. Even among the remaining 38
asymptomatic patients, 79% still fulfilled
surgical criteria. Consequently, only 7% of
these patients were not scheduled for sur-
gery (8 of 115 patients). These results agree
with data obtained in other developing coun-
tries which also do not perform routine cal-
cium measurements (6,17). The biochemi-
cal parameters of symptomatic patients were
more compromised at presentation than those
of asymptomatic patients, but BMD was
reduced in both groups, with no significant
difference between them.
Considering the surgical guidelines pro-
posed for asymptomatic patients with PHP,
Silverberg and Bilezikian (5) reported that
about 50% of these patients would meet at
least one surgical criterion. Although we
consider our high prevalence of sympto-
matic patients (66%) and of surgical patients
(93%) to be mainly a consequence of de-
layed diagnosis, it is also possible that dif-
ferences in the genetic and racial backgrounds
of our population may play a role. These
differences could be somehow modulated
by local environmental factors such as low
calcium intake and vitamin D deficiency. As
a consequence of the high racial admixture
of our population, it is extremely difficult, if
not impossible, to appropriately separate the
different Brazilian ethnic groups. Calcium
and vitamin D deficiencies have been re-
lated to the clinical profile of PHP (18).
Moosgaard et al. (19) demonstrated that vi-
tamin D deficiency or insufficiency is a com-
mon finding in PHP patients and occurs
more often than in gender- and age-matched
controls. As observed in endemic areas of
vitamin D deficiency, low levels of vitamin
D could be related to a more aggressive
clinical presentation of PHP, with greater
adenoma size and overt bone disease (10,15).
Since we do not have data regarding the
vitamin D status of our patients we cannot
rule out this possibility.
As stated earlier, we observed a high
prevalence of parathyroid carcinoma in our
series, similar to those found in other series
from developing countries (6,17). Our cases
were based on surgical findings such as large
and poorly circumscribed tumors adherent
to the surrounding soft tissues of the neck or
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of the thyroid gland and on pathological
findings such as capsular and vascular inva-
sion (20). Unfortunately, the follow-up of
these cases is limited: three have died be-
cause of complications related to hypercal-
cemia and the remaining ones were followed
for a mean period of only 24 months (21).
BMD determinations by DEXA provide
a noninvasive and objective parameter of
disease activity in PHP. In addition, avail-
able data indicate that DEXA can be used to
classify patients with PHP and can be help-
ful regarding the decision about recommend-
ing surgery or not for individual patients. In
our study we found a high prevalence of
osteoporosis (71%). Several studies have
shown that regional BMD is decreased by 10
to 20% in untreated PHP patients, with greater
involvement of the appendicular skeleton,
which is compatible with a preferential cor-
tical bone involvement in PHP (22). These
densitometric studies as well as histomor-
phometric data have shown that high iPTH
levels have a catabolic action on cortical
bone and an anabolic action on trabecular
bone, with relative preservation of bone mass
in the lumbar spine (22). However, in our
study, most of the osteoporotic patients had
involvement of both femoral neck and lum-
bar spine BMD, with no preservation of
lumbar spine BMD. Indeed, at presentation
there were no differences in lumbar spine or
femoral neck BMD between symptomatic
and asymptomatic patients. In a 10-year fol-
low-up study, 21% of asymptomatic PHP
patients had a bone loss of more than 10% at
one or more sites, whereas BMD was pre-
served in the remaining ones (23).
The remarkable BMD recovery observed
in our patients after surgical treatment agrees
with other studies. Silverberg et al. (24)
found an increase of 12 to 13% in both
lumbar spine and femoral neck BMD 4 years
after parathyroidectomy. Nevertheless, it
should be emphasized that these results were
obtained for a majority of asymptomatic
patients (76%), with similar BMD compared
to patients without surgical criteria in that
study. Our patients differed in this context
because, although symptomatic and asymp-
tomatic patients meeting surgical criteria had
similar BMD reductions, their reductions
were greater than in patients without surgi-
cal criteria. Three years after surgery, our
patients had BMD increases of 19.4% in the
lumbar spine and of 15.7% in the femoral
neck, and symptomatic patients had greater
increases of BMD than asymptomatic pa-
tients (23 vs 12% in the lumbar spine and 19
vs 10% in the femoral neck, respectively).
Our asymptomatic patients also had signifi-
cant increases in BMD, with results similar
to those reported in the literature (23,24).
Given this and the fact that parathyroidec-
tomy is a low-risk procedure, we conclude
that asymptomatic patients meeting surgical
criteria for parathyroidectomy (5) should be
submitted to surgery.
In this retrospective study we reviewed
data of PHP patients seen at our institution
during the last 20 years, and our results
support previous findings of a predominantly
symptomatic disease. This PHP presenta-
tion profile could be mainly related to a
delayed diagnosis and may reflect the fact
that we are seeing only the more severe
cases. Nevertheless, one should consider that
genetic and racial backgrounds as well as
nutritional factors such as calcium and vita-
min D deficiency may play a role in the
clinical presentation of PHP in Brazilian
patients. The surgical treatment was suc-
cessful in almost all the patients and recov-
ery of BMD reached 19.4% in the lumbar
spine and 15.7% in the femoral neck 3 years
after surgery.
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